lncRNA PVT1 in the Pathogenesis and Clinical Management of
Renal Cell Carcinoma

J 2021

lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma

BOHOŠOVÁ, Júlia, Adéla KUBÍČKOVÁ and Ondřej SLABÝ

Basic information

Original name

lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma

Authors

BOHOŠOVÁ, Júlia (703 Slovakia, belonging to the institution), Adéla KUBÍČKOVÁ (203 Czech Republic, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Biomolecules, BASEL, MDPI, 2021, 2218-273X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.064

RIV identification code

RIV/00216224:14110/21:00120232

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/biom11050664

UT WoS

000653480900001

Keywords in English

biomarker; prognosis; diagnosis; long non-coding RNA; tumorigenesis

Abstract

V originále

LncRNA PVT1 (plasmacytoma variant translocation 1) has become a staple of the lncRNA profile in patients with renal cell carcinoma (RCC). Common dysregulation in renal tumors outlines the essential role of PVT1 in the development of RCC. There is already a plethora of publications trying to uncover the cellular mechanisms of PVT1-mediated regulation and its potential exploitation in management of RCC. In this review, we summarize the literature focused on PVT1 in RCC and aim to synthesize the current knowledge on its role in the cells of the kidney. Further, we provide an overview of the lncRNA profiling studies that have identified a more or less significant association of PVT1 with the clinical behavior of RCC. Based on our search, we analyzed the 17 scientific papers discussed in this review that provide robust support for the indispensable role of PVT1 in RCC development and future personalized therapy.

Links

NV18-03-00554, research and development project

Name: Molekulární klasifikace renálního buněčného karcinomu založená na expresi dlouhých nekódujících RNA a její využití v diagnostice, předpovědi prognózy a terapii

Investor: Ministry of Health of the CR

Citovat

BOHOŠOVÁ, Júlia, Adéla KUBÍČKOVÁ and Ondřej SLABÝ. lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma. Biomolecules. BASEL: MDPI, 2021, vol. 11, No 5, p. 1-12. ISSN 2218-273X. Available from: https://dx.doi.org/10.3390/biom11050664.

@article{1836841,
   author = {Bohošová, Júlia and Kubíčková, Adéla and Slabý, Ondřej},
   article_location = {BASEL},
   article_number = {5},
   doi = {http://dx.doi.org/10.3390/biom11050664},
   keywords = {biomarker; prognosis; diagnosis; long non-coding RNA; tumorigenesis},
   language = {eng},
   issn = {2218-273X},
   journal = {Biomolecules},
   title = {lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma},
   url = {https://www.mdpi.com/2218-273X/11/5/664},
   volume = {11},
   year = {2021}
}

TY  - JOUR
ID  - 1836841
AU  - Bohošová, Júlia - Kubíčková, Adéla - Slabý, Ondřej
PY  - 2021
TI  - lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma
JF  - Biomolecules
VL  - 11
IS  - 5
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 2218273X
KW  - biomarker
KW  - prognosis
KW  - diagnosis
KW  - long non-coding RNA
KW  - tumorigenesis
UR  - https://www.mdpi.com/2218-273X/11/5/664
N2  - LncRNA PVT1 (plasmacytoma variant translocation 1) has become a staple of the lncRNA profile in patients with renal cell carcinoma (RCC). Common dysregulation in renal tumors outlines the essential role of PVT1 in the development of RCC. There is already a plethora of publications trying to uncover the cellular mechanisms of PVT1-mediated regulation and its potential exploitation in management of RCC. In this review, we summarize the literature focused on PVT1 in RCC and aim to synthesize the current knowledge on its role in the cells of the kidney. Further, we provide an overview of the lncRNA profiling studies that have identified a more or less significant association of PVT1 with the clinical behavior of RCC. Based on our search, we analyzed the 17 scientific papers discussed in this review that provide robust support for the indispensable role of PVT1 in RCC development and future personalized therapy.
ER  -

BOHOŠOVÁ, Júlia, Adéla KUBÍČKOVÁ and Ondřej SLABÝ. lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma. \textit{Biomolecules}. BASEL: MDPI, 2021, vol.~11, No~5, p.~1-12. ISSN~2218-273X. Available from: https://dx.doi.org/10.3390/biom11050664.

Detailed Information on Publication Record